Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer
| Autor: | Peng Huang, Dengjie Ouyang, Pei Chen, Rooh-Afza Khushbu, Mian Liu, Hai-Long Tan, Shi Chang, Hui-Yu Hu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Proto-Oncogene Proteins B-raf
0301 basic medicine Cancer Research medicine.medical_specialty endocrine system diseases medicine.disease_cause Papillary thyroid cancer Pathogenesis 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine medicine Humans Anaplastic Lymphoma Kinase Thyroid Neoplasms Receptor trkA Protein Kinase Inhibitors Gene Thyroid cancer Mutation Hematology Kinase business.industry Proto-Oncogene Proteins c-ret General Medicine medicine.disease 030104 developmental biology Oncology Thyroid Cancer Papillary 030220 oncology & carcinogenesis Cancer research Gene Fusion business Protein Kinases |
| Zdroj: | Journal of Cancer Research and Clinical Oncology. 147:323-337 |
| ISSN: | 1432-1335 0171-5216 |
| Popis: | The incidence of papillary thyroid cancer (PTC), the major type of thyroid cancer, is increasing rapidly around the world, and its pathogenesis is still unclear. There is poor prognosis for PTC involved in rapidly progressive tumors and resistance to radioiodine therapy. Kinase gene fusions have been discovered to be present in a wide variety of malignant tumors, and an increasing number of novel types have been detected in PTC, especially progressive tumors. As a tumor-driving event, kinase fusions are constitutively activated or overexpress their kinase function, conferring oncogenic potential, and their frequency is second only to BRAFV600E mutation in PTC. Diverse forms of kinase fusions have been observed and are associated with specific pathological features of PTC (usually at an advanced stage), and clinical trials of therapeutic strategies targeting kinase gene fusions are feasible for radioiodine-resistant PTC. This review summarizes the roles of kinase gene fusions in PTC and the value of clinical therapy of targeting fusions in progressive or refractory PTC, and discusses the future perspectives and challenges related to kinase gene fusions in PTC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink